Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Author： El Rassi Fuad Bergsagel John D. Arellano Martha Gaddh Manila Jillella Anand Kota Vamsi Heffner Leonard T. Winton Elliott F. Khoury Hanna Jean

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|6|872-875

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.6, 2015-03, pp. : 872-875

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia Kantarjian Hagop Cortes Jorge Ohanian Maro Jabbour Elias

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for chronic myeloid leukemia

By Cilloni Daniela Messa Emanuela Rotolo Antonia Saglio Giuseppe

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 175-184

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in Chronic Myeloid Leukemia

Current Cancer Drug Targets, Vol. 12, Iss. 5, 2012-05 ,pp. : 458-470

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Drugs in Chronic Myeloid Leukemia

Current Medicinal Chemistry, Vol. 15, Iss. 29, 2008-12 ,pp. : 3036-3051

Bentham Science Publishers

Access to resources Recommend Favorite

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-α Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

By Reed Shelby D. Anstrom Kevin J. Li Yanhong Schulman Kevin A.

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite